 "Divis Labs sheds 14% in two days, hits 52-week low post Q4 results")
Shares of Divis Laboratories hit a 52-week low of Rs 3,708, down 4 per cent on the BSE in Tuesday’s trade so far. The stock has slipped 14 per cent in the past two trading days despite the pharmaceutical company delivering a better-than-expected March quarter (Q4FY22) results, with the highest-ever quarterly sales and earnings before interest, taxes, depreciation, and amortization (EBITDA). The board recommended a dividend of Rs 30 per share of face value Rs 2 each i.e., 1500 per cent for the financial year 2021-22.
The stock has fallen below its previous low of Rs 3,790 touched on January 24, 2022.
The company’s consolidated revenues grew 41 per cent year on year (YoY) to Rs 2,518 crore. EBITDA grew 54 per cent YoY to Rs 1,104 crore, while margins improved 380 bps YoY to 43.9 per cent mainly due to lower employee and other expenditure. Net profit grew 78 per cent YoY to Rs 895 crore. The performance was largely led by strong traction in the Custom Synthesis (CS) segment.
Motilal Oswal Financial Services lowered its FY23/FY24 EPS estimate by 11 per ecnt/14 per cent, factoring in reduced sales of COVID-related products, considering the low number of cases globally, a gradual uptick in growth in the Generics segment, and delay in implementation of Kakinada capex.
“More than strong quarterly performance, the important narrative for Divi’s is its unprecedented capex plans to further augment capacities besides preparing for growing opportunities arising due to China plus one factor. It has earmarked an aggressive capex of around Rs 2,000 crore (including greenfield Kakinada plant) over next two years in order to take a chunk of ~US$20 billion opportunity of APIs going off-patent over FY23-25,” ICICI Securities said in a note. Divi’s remains a quintessential play on the Indian API/CRAMs segment with its product offerings and execution prowess, the brokerage firm said.
The stock has fallen below its previous low of Rs 3,790 touched on January 24, 2022.
The company’s consolidated revenues grew 41 per cent year on year (YoY) to Rs 2,518 crore. EBITDA grew 54 per cent YoY to Rs 1,104 crore, while margins improved 380 bps YoY to 43.9 per cent mainly due to lower employee and other expenditure. Net profit grew 78 per cent YoY to Rs 895 crore. The performance was largely led by strong traction in the Custom Synthesis (CS) segment.
Motilal Oswal Financial Services lowered its FY23/FY24 EPS estimate by 11 per ecnt/14 per cent, factoring in reduced sales of COVID-related products, considering the low number of cases globally, a gradual uptick in growth in the Generics segment, and delay in implementation of Kakinada capex.
“More than strong quarterly performance, the important narrative for Divi’s is its unprecedented capex plans to further augment capacities besides preparing for growing opportunities arising due to China plus one factor. It has earmarked an aggressive capex of around Rs 2,000 crore (including greenfield Kakinada plant) over next two years in order to take a chunk of ~US$20 billion opportunity of APIs going off-patent over FY23-25,” ICICI Securities said in a note. Divi’s remains a quintessential play on the Indian API/CRAMs segment with its product offerings and execution prowess, the brokerage firm said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%